CLL/SLL Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about CLL/SLL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 2

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL+4 more
Zulfa Omer22 enrolled1 locationNCT07108998
Recruiting
Phase 2

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland60 enrolled18 locationsNCT04523428
Recruiting
Phase 1

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

CLL/SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Lomond Therapeutics Holdings, Inc.66 enrolled4 locationsNCT06708897
Recruiting
Phase 3

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL
Ascentage Pharma Group Inc.400 enrolled2 locationsNCT06104566
Recruiting
Phase 2

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL/SLL+1 more
Zulfa Omer34 enrolled1 locationNCT06978088
Recruiting
Phase 1

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

CLL/SLL
Ascentage Pharma Group Inc.144 enrolled9 locationsNCT04215809
Recruiting

Current Status of BTKi Treatment for CLL/SLL in China

CLL/SLL
The First Affiliated Hospital with Nanjing Medical University1,000 enrolled1 locationNCT06508684
Recruiting
Phase 3

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

CLL/SLL
Ascentage Pharma Group Inc.344 enrolled6 locationsNCT06319456
Recruiting
Phase 1Phase 2

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland112 enrolled24 locationsNCT05791409